Lindsay Hersh Autz

Special Counsel

Thank you for your interest. Before you communicate with one of our attorneys, please note: Any comments our attorneys share with you are general information and not legal advice. No attorney-client relationship will exist between you or your business and O’Melveny or any of its attorneys unless conflicts have been cleared, our management has given its approval, and an engagement letter has been signed. Meanwhile, you agree: we have no duty to advise you or provide you with legal assistance; you will not divulge any confidences or send any confidential or sensitive information to our attorneys (we are not in a position to keep it confidential and might be required to convey it to our clients); and, you may not use this contact to attempt to disqualify O’Melveny from representing other clients adverse to you or your business. By clicking "accept" you acknowledge receipt and agree to all of the terms of this paragraph and our Disclaimer.

pdf

Lindsay Hersh Autz is a counsel in O’Melveny’s New York office and a member of the Intellectual Property and Technology practice.Her practice focuses on patent litigation, particularly in the areas of biotechnology, pharmaceuticals, and the chemical arts. She has experience in all aspects of patent litigation, including pre-suit investigations and appeals before the Federal Circuit, as well as international arbitration.

Admissions

Bar Admissions

  • New York

Court Admissions

  • US District Court, Eastern and Southern Districts of New York
  • US Court of Appeals, Federal Circuit

Education

  • University of Connecticut, J.D.: with honors; Associate Editor, Connecticut Law Review
  • Tufts University, B.S., Chemical Engineering & Biotechnology: cum laude

Professional Activities

Member

  • American Bar Association
  • New York Intellectual Property Law Association
  • Represented international pharmaceutical companies against generic companies on patents related to anti-platelet treatment
  • Represented international pharmaceutical companies against generic companies on a patent covering a drug to treat attention deficit disorder
  • Represented international pharmaceutical company in an arbitration before the ICC International Court of Arbitration concerning royalties due under a terminated license involving eukaryotic protein expression technologies
  • Represented international pharmaceutical company against biotechnology companies on patents covering eukaryotic protein expression technologies
  • Represented international pharmaceutical company against generic companies on a patent covering a treatment for symptoms of Sjögren’s Syndrome